Upfront Briefing
Oncology gave a reminder that Phase 3 is an unforgiving referee: Immutep’s LAG-3 program failed in lung cancer and TACTI-004 is being discontinued after a futility look.
In the “not all readouts are equal” column, Ultragenyx hit a key primary endpoint in Phase 3 for OTC deficiency, while GSK picked up broader FDA clearance for Arexvy — one de-risking a late-stage rare disease asset, the other extending the life-cycle of a commercial vaccine franchise.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,632.2 |
(0.6%) |
(3.1%) |
| Nasdaq 100 |
24,380.7 |
(0.6%) |
(3.4%) |
| Russell 2000 |
2,480.1 |
(0.4%) |
(0.1%) |
| Healthcare (XLV) |
149.8 |
(0.3%) |
(3.2%) |
| Biotech (XBI) |
121.8 |
(0.6%) |
(0.1%) |
| Nasdaq Biotech (NBI) |
5,715.5 |
(0.5%) |
+0.2% |
| Clinical Trials (BBC) |
40.7 |
(1.8%) |
+5.4% |
|
- Macro drove the red tape: oil spiked with Brent settling above $100, Q4 GDP was revised lower, and inflation/rates worries pushed investors toward fewer near-term Fed cuts — a rough setup for duration-sensitive growth.
- Defensives held up better than biotech beta: XLV fell less than the S&P 500, while XBI, NBI and especially BBC underperformed as investors de-risked SMID-cap and clinical-stage exposure first.
The Big 3
|
1
|
Immutep's LAG-3 drug fails Phase 3 lung cancer study
|
- Immutep's LAG-3 drug failed its Phase 3 lung cancer study, leading to the discontinuation of the TACTI-004 trial after a futility analysis.
- Why it matters: A Phase 3 futility stop is more than a trial miss: it pressures the standalone value of eftilagimod alpha, weakens the combo-immuno-oncology differentiation case, and reduces strategic optionality at a point when late-stage validation is what drives partnering leverage and commercial credibility.
- Source: Endpoints
- More: PR; BioPharma Dive
|
|
2
|
Ultragenyx gene therapy hits Phase 3 endpoint for OTC deficiency
|
- Ultragenyx's gene therapy achieved a key primary endpoint in its Phase 3 trial for ornithine transcarbamylase (OTC) deficiency, de-risking the rare disease program.
- Why it matters: A positive Phase 3 readout materially improves the regulatory and commercial setup for a high-need rare-disease program, while also reinforcing Ultragenyx’s ability to convert complex genetic-medicine platforms into registrational assets — the key question investors usually discount hardest.
- Source: Endpoints
- More: BioPharma Dive
|
|
3
|
GSK's Arexvy RSV vaccine gets broader FDA clearance |
- GSK's RSV vaccine, Arexvy, received FDA label expansion into adults aged 18–49 who are at increased risk, widening the eligible population as the RSV vaccine market gets more competitive.
- Why it matters: The label expansion into adults aged 18–49 at increased risk broadens Arexvy’s addressable U.S. population, helps GSK defend franchise momentum against Pfizer and Moderna, and gives investors a cleaner line of sight to life-cycle extension rather than a franchise peaking after the initial older-adult launch wave.
- Source: BioPharma Dive
- More: Fierce Pharma
|
Everything Else that broke
- Novartis Cosentyx gets FDA nod for pediatric hidradenitis suppurativa. — PR
- BioVersys gets FDA green light to start pivotal Phase 3 BV100 trial in HABP/VABP. — PR
- Sana reports 14-month insulin production in a Type 1 diabetes patient treated with its islet-cell therapy. — Fierce Biotech
- Insulet recalls certain Omnipod 5 pumps over insulin leak risk. — Fierce Biotech
- FDA biosimilars guidance could lower development friction and widen the eventual market. — BioPharma Dive
- Unixell becomes one of the first China biotechs cleared to test a stem cell-derived epilepsy therapy in the U.S. — BioPharma Dive
- EMA PRAC flags aseptic meningitis risk with Valneva’s Ixchiq vaccine. — EMA
- Evotec and Vistagen layoffs add to the sector’s ongoing cost-reset theme. — BioPharma Dive
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly
⬇️
|
M&A / BD&L
- No notable fresh M&A / BD&L announcements surfaced in the biotech tape since Friday morning.
VC / Private Financings
- Equillium announces a $35M PIPE led solely by RA Capital Management. — PR
IPOs / Follow-Ons
- Xenon and Dianthus both upsized follow-ons after books built strongly, a useful read-through on specialist demand for differentiated biotech paper. — BioCentury
|
